Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1549695,T1 relaxivity,With T1 relaxivity values of 8.7 L/mmol.,Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549695/),[l] / [mM],8.7,5135,DB00789,Gadopentetate dimeglumine
,1549695,biliary transport maximum,"In rats, the biliary transport maximum was 5 mumol gadolinium/min.kg.",Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549695/),g·μM,5,5136,DB00789,Gadopentetate dimeglumine
,8486503,serum elimination half-life,"The serum elimination half-life was approximately 70 minutes, and urinary recovery was greater than 95% by 72 hours after administration.",Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8486503/),min,70,9277,DB00789,Gadopentetate dimeglumine
,8486501,half-life,"Its half-life in rats, rabbits, and monkeys was short, 18, 38, and 75 minutes, respectively.","Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8486501/),min,18,12549,DB00789,Gadopentetate dimeglumine
,8486501,half-life,"Its half-life in rats, rabbits, and monkeys was short, 18, 38, and 75 minutes, respectively.","Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8486501/),min,38,12550,DB00789,Gadopentetate dimeglumine
,8486501,half-life,"Its half-life in rats, rabbits, and monkeys was short, 18, 38, and 75 minutes, respectively.","Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8486501/),min,75,12551,DB00789,Gadopentetate dimeglumine
,8240452,Vmax,"Nonlinear pharmacokinetic modeling yielded Vmax values (mumol/min.kg) of 4.34 +/- 0.65 in rats, 2.40 +/- 0.98 in dogs and 0.810 +/- 0.66 in monkeys.",Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240452/),[μM] / [kg·min],4.34,22425,DB00789,Gadopentetate dimeglumine
,8240452,Vmax,"Nonlinear pharmacokinetic modeling yielded Vmax values (mumol/min.kg) of 4.34 +/- 0.65 in rats, 2.40 +/- 0.98 in dogs and 0.810 +/- 0.66 in monkeys.",Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240452/),[μM] / [kg·min],2.40,22426,DB00789,Gadopentetate dimeglumine
,8240452,Vmax,"Nonlinear pharmacokinetic modeling yielded Vmax values (mumol/min.kg) of 4.34 +/- 0.65 in rats, 2.40 +/- 0.98 in dogs and 0.810 +/- 0.66 in monkeys.",Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240452/),[μM] / [kg·min],0.810,22427,DB00789,Gadopentetate dimeglumine
,15323399,CE ratio,"The CE ratio, washout ratio, and k in the periphery in P-VEGF positive breast cancers (mean 178%, 18%, and 1.5 x 10(-2) (s(-1)) were significantly greater (P<0.01, P<0.05, and P<0.03)) than those for P-VEGF negative breast cancers (mean: 151%, 14%, and 1.1 x 10(-2) (s(-1)).","Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15323399/),%,178,27386,DB00789,Gadopentetate dimeglumine
,15323399,washout ratio,"The CE ratio, washout ratio, and k in the periphery in P-VEGF positive breast cancers (mean 178%, 18%, and 1.5 x 10(-2) (s(-1)) were significantly greater (P<0.01, P<0.05, and P<0.03)) than those for P-VEGF negative breast cancers (mean: 151%, 14%, and 1.1 x 10(-2) (s(-1)).","Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15323399/),%,18,27387,DB00789,Gadopentetate dimeglumine
,15323399,washout ratio,"The CE ratio, washout ratio, and k in the periphery in P-VEGF positive breast cancers (mean 178%, 18%, and 1.5 x 10(-2) (s(-1)) were significantly greater (P<0.01, P<0.05, and P<0.03)) than those for P-VEGF negative breast cancers (mean: 151%, 14%, and 1.1 x 10(-2) (s(-1)).","Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15323399/),1/[s],1.5 x 10(-2,27388,DB00789,Gadopentetate dimeglumine
,15323399,washout ratio,"The CE ratio, washout ratio, and k in the periphery in P-VEGF positive breast cancers (mean 178%, 18%, and 1.5 x 10(-2) (s(-1)) were significantly greater (P<0.01, P<0.05, and P<0.03)) than those for P-VEGF negative breast cancers (mean: 151%, 14%, and 1.1 x 10(-2) (s(-1)).","Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15323399/),%,151,27389,DB00789,Gadopentetate dimeglumine
,15323399,k,"The CE ratio, washout ratio, and k in the periphery in P-VEGF positive breast cancers (mean 178%, 18%, and 1.5 x 10(-2) (s(-1)) were significantly greater (P<0.01, P<0.05, and P<0.03)) than those for P-VEGF negative breast cancers (mean: 151%, 14%, and 1.1 x 10(-2) (s(-1)).","Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15323399/),1/[s],1.5 x 10(-2,27390,DB00789,Gadopentetate dimeglumine
,15323399,k,"The CE ratio, washout ratio, and k in the periphery in P-VEGF positive breast cancers (mean 178%, 18%, and 1.5 x 10(-2) (s(-1)) were significantly greater (P<0.01, P<0.05, and P<0.03)) than those for P-VEGF negative breast cancers (mean: 151%, 14%, and 1.1 x 10(-2) (s(-1)).","Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15323399/),%,151,27391,DB00789,Gadopentetate dimeglumine
,22452401,molecular weight (Mw),"Earlier described dextran-based contrast agents for magnetic resonance imaging (MRI) comprising the gadolinium chelate diethylenetriamine pentaacetic acid (GdDTPA, 1) have shown significantly shorter in vivo contrast duration in rat than what would be expected from the initial average molecular weight (Mw) of the dextran fraction (71.4 kD).",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),k,71.4,28466,DB00789,Gadopentetate dimeglumine
,22452401,molecular weight (Mw),"To investigate this further, four dextran fractions with given initial average molecular weight (Mw) of 10.4, 41.0, 71.4 and 580 kD were used as starting material to prepare products 2-5 where one of the carboxylic acid functionalities in GdDTPA was used as a direct covalent ester linker to hydroxyl groups in dextrans.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),,10.4,28467,DB00789,Gadopentetate dimeglumine
,22452401,molecular weight (Mw),"To investigate this further, four dextran fractions with given initial average molecular weight (Mw) of 10.4, 41.0, 71.4 and 580 kD were used as starting material to prepare products 2-5 where one of the carboxylic acid functionalities in GdDTPA was used as a direct covalent ester linker to hydroxyl groups in dextrans.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),,41.0,28468,DB00789,Gadopentetate dimeglumine
,22452401,molecular weight (Mw),"To investigate this further, four dextran fractions with given initial average molecular weight (Mw) of 10.4, 41.0, 71.4 and 580 kD were used as starting material to prepare products 2-5 where one of the carboxylic acid functionalities in GdDTPA was used as a direct covalent ester linker to hydroxyl groups in dextrans.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),,71.4,28469,DB00789,Gadopentetate dimeglumine
,22452401,molecular weight (Mw),"To investigate this further, four dextran fractions with given initial average molecular weight (Mw) of 10.4, 41.0, 71.4 and 580 kD were used as starting material to prepare products 2-5 where one of the carboxylic acid functionalities in GdDTPA was used as a direct covalent ester linker to hydroxyl groups in dextrans.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),,580,28470,DB00789,Gadopentetate dimeglumine
,22452401,Mw,A fifth derivative (6) was an amide-ester bound β-alanine-DTPAGd conjugate with dextran having Mw 71.4 kD.,In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),kd,71.4,28471,DB00789,Gadopentetate dimeglumine
,22452401,t 1/2,"Pharmacokinetic parameters showed that when GdDTPA is ester-bound directly to dextran hydroxyls, the cleavage rates of 2-5 were only moderately dependent on the molecular weights of the dextrans, having blood pool half-lives comparable to the low-molecular reference compound (t 1/2,β 0.3 - 0.5 hrs.).",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),h,0.3 - 0.5,28472,DB00789,Gadopentetate dimeglumine
,22452401,"plasma half-life t 1/2,β","Presence of a β-alanine spacer in 6 prolonged the plasma half-life t 1/2,β to 6.9 hours, rendering a blood residence time suitable for blood pool slow release of GdDTPA.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),h,6.9,28473,DB00789,Gadopentetate dimeglumine
,10924585,cumulative amount of,"The cumulative amount of gadolinium excreted in human breast milk during 24 hours was 0.57 micromol +/- 0.71 (SD; range, 0.05-3.0 micromol).",Gadopentetate dimeglumine excretion into human breast milk during lactation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924585/),μM,0.57,31452,DB00789,Gadopentetate dimeglumine
,10924585,excreted,"The cumulative amount of gadolinium excreted in human breast milk during 24 hours was 0.57 micromol +/- 0.71 (SD; range, 0.05-3.0 micromol).",Gadopentetate dimeglumine excretion into human breast milk during lactation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924585/),μM,0.57,31453,DB00789,Gadopentetate dimeglumine
,10924585,excreted dose,"The excreted dose was thus less than 0.04% of the administered intravenous dose (range, 0.001%-0.04%; mean, 0.009% +/- 0.010) for all cases.",Gadopentetate dimeglumine excretion into human breast milk during lactation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924585/),%,0.001,31454,DB00789,Gadopentetate dimeglumine
,10924585,excreted dose,"The excreted dose was thus less than 0.04% of the administered intravenous dose (range, 0.001%-0.04%; mean, 0.009% +/- 0.010) for all cases.",Gadopentetate dimeglumine excretion into human breast milk during lactation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924585/),%,0.009,31455,DB00789,Gadopentetate dimeglumine
,10512227,distribution time,"Pharmacokinetic analysis showed that recurrent IP had faster (distribution time, 41 versus 88 seconds) and higher (amplitude, 2.4 versus 1.2 arbitrary units) enhancement than did fibrosis or granulation tissue.",Recurrent inverted papilloma: diagnosis with pharmacokinetic dynamic gadolinium-enhanced MR imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10512227/),seconds,41,32132,DB00789,Gadopentetate dimeglumine
,10512227,distribution time,"Pharmacokinetic analysis showed that recurrent IP had faster (distribution time, 41 versus 88 seconds) and higher (amplitude, 2.4 versus 1.2 arbitrary units) enhancement than did fibrosis or granulation tissue.",Recurrent inverted papilloma: diagnosis with pharmacokinetic dynamic gadolinium-enhanced MR imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10512227/),seconds,88,32133,DB00789,Gadopentetate dimeglumine
,10512227,distribution time,A cut-off of 65 seconds for distribution time and 1.6 units for amplitude yielded a sensitivity of 100% and a specificity of 100% for diagnosing recurrent IP.,Recurrent inverted papilloma: diagnosis with pharmacokinetic dynamic gadolinium-enhanced MR imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10512227/),seconds,65,32134,DB00789,Gadopentetate dimeglumine
>,19431058,total tumor necrosis,Six patients had total tumor necrosis of >or=90% and six had a measure of <90%.,Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19431058/),%,90,38419,DB00789,Gadopentetate dimeglumine
<,19431058,total tumor necrosis,Six patients had total tumor necrosis of >or=90% and six had a measure of <90%.,Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19431058/),,90,38420,DB00789,Gadopentetate dimeglumine
,28089499,logKconds,"The logKconds calculated from the rate constants were on the order of ~4-6, and were not significantly altered by excess ligand or phosphate.",The stability of gadolinium-based contrast agents in human serum: A reanalysis of literature data and association with clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089499/),,4-6,39560,DB00789,Gadopentetate dimeglumine
,8497616,blood half-life,The blood half-life of the agent was 14 hours.,"A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8497616/),h,14,40132,DB00789,Gadopentetate dimeglumine
,15607091,"initial enhancement rate, E(R)","The initial enhancement rate, E(R), in regions of interest (ROIs) was found to have a wide range of variation: 5 to 38 min(-1) over the distal femoral physis and 1 to 10 min(-1) in the synovium.",Quantification of dynamic contrast-enhanced MR imaging of the knee in children with juvenile rheumatoid arthritis based on pharmacokinetic modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15607091/),1/[min],5 to 38,49928,DB00789,Gadopentetate dimeglumine
,15607091,"initial enhancement rate, E(R)","The initial enhancement rate, E(R), in regions of interest (ROIs) was found to have a wide range of variation: 5 to 38 min(-1) over the distal femoral physis and 1 to 10 min(-1) in the synovium.",Quantification of dynamic contrast-enhanced MR imaging of the knee in children with juvenile rheumatoid arthritis based on pharmacokinetic modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15607091/),1/[min],1 to 10,49929,DB00789,Gadopentetate dimeglumine
,9702878,A,"Before radiotherapy, the amplitude A was significantly (P < .05) lower in patients with subsequent local tumor control (n = 8; mean A = .34 +/- .15) compared to patients without subsequent local tumor control (n = 10; mean A = .94 +/- .71).",Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9702878/),,.34,50199,DB00789,Gadopentetate dimeglumine
,9702878,A,"Before radiotherapy, the amplitude A was significantly (P < .05) lower in patients with subsequent local tumor control (n = 8; mean A = .34 +/- .15) compared to patients without subsequent local tumor control (n = 10; mean A = .94 +/- .71).",Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9702878/),,.94,50200,DB00789,Gadopentetate dimeglumine
,15282828,fP,"Tissue parameters determined for pectoral muscle (fP = 0.04 +/- 0.01, fI = 0.09 +/- 0.01, F/VP = 2.4 +/- 1.3 min(-1), and KPS/VP = 1.2 +/- 0.5 min(-1)) and 10 histologically proven carcinomas (fP = 0.20 +/- 0.07, fI = 0.34 +/- 0.16, F/VP = 2.4 +/- 0.7 min(-1), and KPS/VP = 0.86 +/- 0.62 min(-1)) agreed reasonable well with literature data.",Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282828/),,0.04,50315,DB00789,Gadopentetate dimeglumine
,15282828,fI,"Tissue parameters determined for pectoral muscle (fP = 0.04 +/- 0.01, fI = 0.09 +/- 0.01, F/VP = 2.4 +/- 1.3 min(-1), and KPS/VP = 1.2 +/- 0.5 min(-1)) and 10 histologically proven carcinomas (fP = 0.20 +/- 0.07, fI = 0.34 +/- 0.16, F/VP = 2.4 +/- 0.7 min(-1), and KPS/VP = 0.86 +/- 0.62 min(-1)) agreed reasonable well with literature data.",Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282828/),,0.09,50316,DB00789,Gadopentetate dimeglumine
,15282828,F/VP,"Tissue parameters determined for pectoral muscle (fP = 0.04 +/- 0.01, fI = 0.09 +/- 0.01, F/VP = 2.4 +/- 1.3 min(-1), and KPS/VP = 1.2 +/- 0.5 min(-1)) and 10 histologically proven carcinomas (fP = 0.20 +/- 0.07, fI = 0.34 +/- 0.16, F/VP = 2.4 +/- 0.7 min(-1), and KPS/VP = 0.86 +/- 0.62 min(-1)) agreed reasonable well with literature data.",Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282828/),1/[min],2.4,50317,DB00789,Gadopentetate dimeglumine
,15282828,F/VP,"Tissue parameters determined for pectoral muscle (fP = 0.04 +/- 0.01, fI = 0.09 +/- 0.01, F/VP = 2.4 +/- 1.3 min(-1), and KPS/VP = 1.2 +/- 0.5 min(-1)) and 10 histologically proven carcinomas (fP = 0.20 +/- 0.07, fI = 0.34 +/- 0.16, F/VP = 2.4 +/- 0.7 min(-1), and KPS/VP = 0.86 +/- 0.62 min(-1)) agreed reasonable well with literature data.",Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282828/),1/[min],1.2,50318,DB00789,Gadopentetate dimeglumine
,15282828,fP,"Tissue parameters determined for pectoral muscle (fP = 0.04 +/- 0.01, fI = 0.09 +/- 0.01, F/VP = 2.4 +/- 1.3 min(-1), and KPS/VP = 1.2 +/- 0.5 min(-1)) and 10 histologically proven carcinomas (fP = 0.20 +/- 0.07, fI = 0.34 +/- 0.16, F/VP = 2.4 +/- 0.7 min(-1), and KPS/VP = 0.86 +/- 0.62 min(-1)) agreed reasonable well with literature data.",Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282828/),,0.20,50319,DB00789,Gadopentetate dimeglumine
,15282828,fI,"Tissue parameters determined for pectoral muscle (fP = 0.04 +/- 0.01, fI = 0.09 +/- 0.01, F/VP = 2.4 +/- 1.3 min(-1), and KPS/VP = 1.2 +/- 0.5 min(-1)) and 10 histologically proven carcinomas (fP = 0.20 +/- 0.07, fI = 0.34 +/- 0.16, F/VP = 2.4 +/- 0.7 min(-1), and KPS/VP = 0.86 +/- 0.62 min(-1)) agreed reasonable well with literature data.",Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282828/),,0.34,50320,DB00789,Gadopentetate dimeglumine
,15282828,F/VP,"Tissue parameters determined for pectoral muscle (fP = 0.04 +/- 0.01, fI = 0.09 +/- 0.01, F/VP = 2.4 +/- 1.3 min(-1), and KPS/VP = 1.2 +/- 0.5 min(-1)) and 10 histologically proven carcinomas (fP = 0.20 +/- 0.07, fI = 0.34 +/- 0.16, F/VP = 2.4 +/- 0.7 min(-1), and KPS/VP = 0.86 +/- 0.62 min(-1)) agreed reasonable well with literature data.",Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282828/),1/[min],2.4,50321,DB00789,Gadopentetate dimeglumine
,15282828,F/VP,"Tissue parameters determined for pectoral muscle (fP = 0.04 +/- 0.01, fI = 0.09 +/- 0.01, F/VP = 2.4 +/- 1.3 min(-1), and KPS/VP = 1.2 +/- 0.5 min(-1)) and 10 histologically proven carcinomas (fP = 0.20 +/- 0.07, fI = 0.34 +/- 0.16, F/VP = 2.4 +/- 0.7 min(-1), and KPS/VP = 0.86 +/- 0.62 min(-1)) agreed reasonable well with literature data.",Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282828/),1/[min],0.86,50322,DB00789,Gadopentetate dimeglumine
,17402781,blood half-lives,"The two candidate compounds with the largest effective molecular sizes, PEG12000-Gen4-(Gd-DTPA)8 and PEG3400-Gen5-(Gd-DTPA)13, had longer blood half-lives, 36 and 73 min, respectively (monoexponential kinetics for both), and showed strong, prolonged MRI enhancement of vessels.",Cascade polymeric MRI contrast media derived from poly(ethylene glycol) cores: initial syntheses and characterizations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402781/),min,36,53177,DB00789,Gadopentetate dimeglumine
,17402781,blood half-lives,"The two candidate compounds with the largest effective molecular sizes, PEG12000-Gen4-(Gd-DTPA)8 and PEG3400-Gen5-(Gd-DTPA)13, had longer blood half-lives, 36 and 73 min, respectively (monoexponential kinetics for both), and showed strong, prolonged MRI enhancement of vessels.",Cascade polymeric MRI contrast media derived from poly(ethylene glycol) cores: initial syntheses and characterizations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402781/),min,73,53178,DB00789,Gadopentetate dimeglumine
,19466380,half-life in brain,"At a dose of 10 microg (0.5 mg/ml), topoCED had a half-life in brain of approximately 1 day and increased the area under the concentration-time curve (AUC) by 28-fold over free topotecan (153.8 vs. 5.5 microg day/g).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),d,1,54877,DB00789,Gadopentetate dimeglumine
,19466380,area under the concentration-time curve (AUC),"At a dose of 10 microg (0.5 mg/ml), topoCED had a half-life in brain of approximately 1 day and increased the area under the concentration-time curve (AUC) by 28-fold over free topotecan (153.8 vs. 5.5 microg day/g).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),[d·μg] / [g],153.8,54878,DB00789,Gadopentetate dimeglumine
,19466380,area under the concentration-time curve (AUC),"At a dose of 10 microg (0.5 mg/ml), topoCED had a half-life in brain of approximately 1 day and increased the area under the concentration-time curve (AUC) by 28-fold over free topotecan (153.8 vs. 5.5 microg day/g).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),[d·μg] / [g],5.5,54879,DB00789,Gadopentetate dimeglumine
,19466380,50% inhibitory concentration (IC(50)),"In a U87MG cell assay, the 50% inhibitory concentration (IC(50)) of topoCED was approximately 0.8 microM at 48 and 72 h; its concentration-time curves were similar to free topotecan and unaffected by gadoCED.",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),μM,0.8,54880,DB00789,Gadopentetate dimeglumine
,19466380,overall survival,"In a U87MG intracranial rat xenograft model, a two-dose CED regimen of topoCED co-infused with gadoCED greatly increased median overall survival at dose levels of 0.5 mg/ml (29.5 days) and 1.0 mg/ml (33.0 days) vs. control (20.0 days; P < 0.0001 for both comparisons).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),d,29.5,54881,DB00789,Gadopentetate dimeglumine
,19466380,overall survival,"In a U87MG intracranial rat xenograft model, a two-dose CED regimen of topoCED co-infused with gadoCED greatly increased median overall survival at dose levels of 0.5 mg/ml (29.5 days) and 1.0 mg/ml (33.0 days) vs. control (20.0 days; P < 0.0001 for both comparisons).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),d,33.0,54882,DB00789,Gadopentetate dimeglumine
,19466380,overall survival,"In a U87MG intracranial rat xenograft model, a two-dose CED regimen of topoCED co-infused with gadoCED greatly increased median overall survival at dose levels of 0.5 mg/ml (29.5 days) and 1.0 mg/ml (33.0 days) vs. control (20.0 days; P < 0.0001 for both comparisons).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),d,20.0,54883,DB00789,Gadopentetate dimeglumine
,17674155,half-life,The in vivo half-life of Gd-DTPA was about 22 min while that of Gd-albumin was about 5.3 h.,Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674155/),min,22,55819,DB00789,Gadopentetate dimeglumine
,17674155,half-life,The in vivo half-life of Gd-DTPA was about 22 min while that of Gd-albumin was about 5.3 h.,Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674155/),h,5.3,55820,DB00789,Gadopentetate dimeglumine
,16896701,half-lives,"The median half-lives of the GFR marker after injection of gadopentetate (1,730 min) and mannitol 1.96 Osm/kg H2O (2,782 min) did not differ statistically (P = 0.28), but were significantly longer than after all other solutions (P < 0.001).",Gadolinium contrast media are more nephrotoxic than iodine media. The importance of osmolality in direct renal artery injections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896701/),min,"1,730",56169,DB00789,Gadopentetate dimeglumine
,16896701,half-lives,"The median half-lives of the GFR marker after injection of gadopentetate (1,730 min) and mannitol 1.96 Osm/kg H2O (2,782 min) did not differ statistically (P = 0.28), but were significantly longer than after all other solutions (P < 0.001).",Gadolinium contrast media are more nephrotoxic than iodine media. The importance of osmolality in direct renal artery injections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896701/),min,"2,782",56170,DB00789,Gadopentetate dimeglumine
,29117483,CNR,"Results Aorta versus muscle CNR (mean ± standard deviation) with Mn-PyC3A and Gd-DTPA was 476 ± 77 and 538 ± 120, respectively (P = .11).","A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117483/),,476,56478,DB00789,Gadopentetate dimeglumine
,29117483,CNR,"Results Aorta versus muscle CNR (mean ± standard deviation) with Mn-PyC3A and Gd-DTPA was 476 ± 77 and 538 ± 120, respectively (P = .11).","A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117483/),,538,56479,DB00789,Gadopentetate dimeglumine
,29117483,CNR,"Brachiocephalic artery versus muscle CNR was 524 ± 55 versus 518 ± 140, respectively (P = .95).","A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117483/),,524,56480,DB00789,Gadopentetate dimeglumine
,29117483,CNR,"Brachiocephalic artery versus muscle CNR was 524 ± 55 versus 518 ± 140, respectively (P = .95).","A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117483/),,518,56481,DB00789,Gadopentetate dimeglumine
,29117483,area under the curve between 0 and 30 minutes,"Mn-PyC3A was eliminated via renal and hepatobiliary excretion with similar pharmacokinetics to Gd-DTPA (area under the curve between 0 and 30 minutes, 20.2 ± 3.1 and 17.0 ± 2.4, respectively; P = .23).","A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117483/),,20.2,56482,DB00789,Gadopentetate dimeglumine
,29117483,area under the curve between 0 and 30 minutes,"Mn-PyC3A was eliminated via renal and hepatobiliary excretion with similar pharmacokinetics to Gd-DTPA (area under the curve between 0 and 30 minutes, 20.2 ± 3.1 and 17.0 ± 2.4, respectively; P = .23).","A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117483/),,17.0,56483,DB00789,Gadopentetate dimeglumine
,1743922,serum elimination half-life,The serum elimination half-life was approximately 70 minutes.,"A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743922/),min,70,64249,DB00789,Gadopentetate dimeglumine
,18292474,attenuation-osmotic ratio,To prospectively compare nephrotoxicity and radiodensity of plasma hyperosmotic gadolinium chelates (attenuation-osmotic ratio of 1:1) with those of plasma iso-osmotic iodine-based contrast media (attenuation-osmotic ratio of 3:1 or 6:1) after renal arteriography in ischemic porcine kidneys.,Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18292474/),,1:1,68352,DB00789,Gadopentetate dimeglumine
,18292474,attenuation-osmotic ratio,To prospectively compare nephrotoxicity and radiodensity of plasma hyperosmotic gadolinium chelates (attenuation-osmotic ratio of 1:1) with those of plasma iso-osmotic iodine-based contrast media (attenuation-osmotic ratio of 3:1 or 6:1) after renal arteriography in ischemic porcine kidneys.,Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18292474/),,3:1,68353,DB00789,Gadopentetate dimeglumine
,18292474,attenuation-osmotic ratio,To prospectively compare nephrotoxicity and radiodensity of plasma hyperosmotic gadolinium chelates (attenuation-osmotic ratio of 1:1) with those of plasma iso-osmotic iodine-based contrast media (attenuation-osmotic ratio of 3:1 or 6:1) after renal arteriography in ischemic porcine kidneys.,Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18292474/),,6:1,68354,DB00789,Gadopentetate dimeglumine
,18292474,plasma half-life elimination time,"Gadobutrol was the only contrast medium to show no sign of excretion, and its plasma half-life elimination time (median, 1103 minutes; P < .001) was significantly longer than that of other contrast agents.",Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18292474/),min,1103,68355,DB00789,Gadopentetate dimeglumine
,18292474,plasma half-life elimination time,"Gadodiamide had a significantly longer plasma half-life elimination time (median, 209 minutes; P = .01) than did iodine-based contrast media (median, 136-142 minutes).",Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18292474/),min,209,68356,DB00789,Gadopentetate dimeglumine
,18292474,plasma half-life elimination time,"Gadodiamide had a significantly longer plasma half-life elimination time (median, 209 minutes; P = .01) than did iodine-based contrast media (median, 136-142 minutes).",Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18292474/),min,136-142,68357,DB00789,Gadopentetate dimeglumine
,18834869,dynamic range,The reportable dynamic range is 3-600 micromol/l Gd.,Automated colorimetric gadolinium assay for verification of clearance and estimation of glomerular filtration rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834869/),[μM] / [l],3-600,71123,DB00789,Gadopentetate dimeglumine
,29651770,logKa,"In normothermic mice, the logKa values for the test and control groups were 0.037 and 0.277 respectively, thus not significantly different (p = 0.404).",The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29651770/),,0.037,72717,DB00789,Gadopentetate dimeglumine
,29651770,logKa,"In normothermic mice, the logKa values for the test and control groups were 0.037 and 0.277 respectively, thus not significantly different (p = 0.404).",The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29651770/),,0.277,72718,DB00789,Gadopentetate dimeglumine
,17191767,relaxivity,NMRD measurements revealed that at 20 MHz and 310 K the relaxivity of the [(Gd-DTPA-phen)3Fe]- is equal to 9.5 +/- 0.3 s(-1) mM(-1) of Gd (28.5 s(-1) per millimole per liter of complex) which is significantly higher than that for Gd-DTPA (3.9 s(-1) mM(-1)).,Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17191767/),1/[mM·s],9.5,75726,DB00789,Gadopentetate dimeglumine
,17191767,relaxivity,NMRD measurements revealed that at 20 MHz and 310 K the relaxivity of the [(Gd-DTPA-phen)3Fe]- is equal to 9.5 +/- 0.3 s(-1) mM(-1) of Gd (28.5 s(-1) per millimole per liter of complex) which is significantly higher than that for Gd-DTPA (3.9 s(-1) mM(-1)).,Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17191767/),1/[l·millimole·s],28.5,75727,DB00789,Gadopentetate dimeglumine
,17191767,relaxivity,NMRD measurements revealed that at 20 MHz and 310 K the relaxivity of the [(Gd-DTPA-phen)3Fe]- is equal to 9.5 +/- 0.3 s(-1) mM(-1) of Gd (28.5 s(-1) per millimole per liter of complex) which is significantly higher than that for Gd-DTPA (3.9 s(-1) mM(-1)).,Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17191767/),1/[mM·s],3.9,75728,DB00789,Gadopentetate dimeglumine
less,8821524,AUC ratio,The AUC ratio of fetal to maternal blood was less than 0.1.,Placental transfer and milk secretion of gadodiamide injection in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8821524/),,0.1,78029,DB00789,Gadopentetate dimeglumine
,23262793,τr,"Low values of τr were characteristic for malignant tumors, and high values were typical for benign lesions; τr of 200 seconds best separated malignant from benign tumors.",Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23262793/),seconds,200,82710,DB00789,Gadopentetate dimeglumine
>,23262793,τr,"On the basis of this pharmacokinetic model, the contrast media-induced time curves on dynamic contrast-enhanced magnetic resonance mammography can be classified by a single kinetic parameter, the tumor flow residence time τr, into benign (τr >200 seconds) and malignant (τr <200 seconds) curve shapes.",Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23262793/),seconds,200,82711,DB00789,Gadopentetate dimeglumine
<,23262793,τr,"On the basis of this pharmacokinetic model, the contrast media-induced time curves on dynamic contrast-enhanced magnetic resonance mammography can be classified by a single kinetic parameter, the tumor flow residence time τr, into benign (τr >200 seconds) and malignant (τr <200 seconds) curve shapes.",Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23262793/),seconds,200,82712,DB00789,Gadopentetate dimeglumine
,17899608,MW(eff),"DCE MRI data from human mammary tumors (MDA-MB-435) implanted in nude mice using low (Gd-DTPA, MW approximately equal 0.6 kDa), medium (Gadomer-17, MW(eff) approximately equal 35 kDa), and high (PG-Gd-DTPA, MW approximately equal 220 kDa) molecular weight contrast agents were analyzed with single- and dual-tracer pharmacokinetic models.","Comparison of single- and dual-tracer pharmacokinetic modeling of dynamic contrast-enhanced MRI data using low, medium, and high molecular weight contrast agents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17899608/),kda,35,83191,DB00789,Gadopentetate dimeglumine
,15776492,relaxivity,Nuclear magnetic relaxation dispersion (NMRD) measurements indicate that at 20 MHz and 37 degrees C the dinuclear gadolinium(III) complex has a much higher relaxivity than [Gd(DTPA)] (6.8 vs 3.9 s(-1) mmol(-1)).,"Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776492/),1/[mmol·s],6.8,84316,DB00789,Gadopentetate dimeglumine
,15776492,relaxivity,Nuclear magnetic relaxation dispersion (NMRD) measurements indicate that at 20 MHz and 37 degrees C the dinuclear gadolinium(III) complex has a much higher relaxivity than [Gd(DTPA)] (6.8 vs 3.9 s(-1) mmol(-1)).,"Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776492/),1/[mmol·s],3.9,84317,DB00789,Gadopentetate dimeglumine
,15776492,relaxivity,"In the presence of human serum albumin (HSA) the relaxivity value of the noncovalently bound dinuclear complex increases to 15.2 s(-1) per mmol of Gd3+, due to its relatively strong interaction with this protein.","Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776492/),1/[mM·s],15.2,84318,DB00789,Gadopentetate dimeglumine
,15776492,binding constant,The fitted value of the binding constant to HSA (Ka) was found to be 10(4) M(-1).,"Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776492/),1/[M],10(4),84319,DB00789,Gadopentetate dimeglumine
,15776492,Ka),The fitted value of the binding constant to HSA (Ka) was found to be 10(4) M(-1).,"Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776492/),1/[M],10(4),84320,DB00789,Gadopentetate dimeglumine
,18434058,K(trans),"Statistically significant differences were observed between the 1.5 and 3T groups for K(trans) (mean+/-S.D.; 5.44+/-2.27 vs. 1.01+/-0.41, respectively) and v(e) (3.37+/-2.32 vs. 0.81+/-0.80).",Pharmacokinetic MR analysis of the cartilage is influenced by field strength. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434058/),,5.44,88636,DB00789,Gadopentetate dimeglumine
,18434058,K(trans),"Statistically significant differences were observed between the 1.5 and 3T groups for K(trans) (mean+/-S.D.; 5.44+/-2.27 vs. 1.01+/-0.41, respectively) and v(e) (3.37+/-2.32 vs. 0.81+/-0.80).",Pharmacokinetic MR analysis of the cartilage is influenced by field strength. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434058/),,1.01,88637,DB00789,Gadopentetate dimeglumine
,18434058,v(e),"Statistically significant differences were observed between the 1.5 and 3T groups for K(trans) (mean+/-S.D.; 5.44+/-2.27 vs. 1.01+/-0.41, respectively) and v(e) (3.37+/-2.32 vs. 0.81+/-0.80).",Pharmacokinetic MR analysis of the cartilage is influenced by field strength. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434058/),,3.37,88638,DB00789,Gadopentetate dimeglumine
,18434058,v(e),"Statistically significant differences were observed between the 1.5 and 3T groups for K(trans) (mean+/-S.D.; 5.44+/-2.27 vs. 1.01+/-0.41, respectively) and v(e) (3.37+/-2.32 vs. 0.81+/-0.80).",Pharmacokinetic MR analysis of the cartilage is influenced by field strength. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434058/),,0.81,88639,DB00789,Gadopentetate dimeglumine
,25932605,half-life,"Following withdrawal of the compound, the half-life of Gd-DTPA in the brain was estimated as 3.1 days based on first-order pharmacokinetics.",Continuous intraputamenal convection-enhanced delivery in adult rhesus macaques. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25932605/),d,3.1,89204,DB00789,Gadopentetate dimeglumine
less,15304969,Tmax,"Among the selected pixels in the tumors 6 days after carbon irradiation, 77% had Tmax values of less than 120 sec, significantly more than in the No-R group.",Changes in the pharmacokinetics of Gd-DTPA in experimental tumors after charged particle radiation: comparison with gamma-ray radiation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304969/),s,120,89518,DB00789,Gadopentetate dimeglumine
,2354925,blood pool half-life,Biodistribution showed a prolonged blood pool phase for Gd-DTPA liposomes with a blood pool half-life of approximately 4 hours for the 100-nm liposomes.,Biodistribution and clearance of liposomal gadolinium-DTPA. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354925/),h,4,92654,DB00789,Gadopentetate dimeglumine
,2354925,half-life,Clearance of gadolinium from the liver and spleen showed a half-life of 3 to 4 days.,Biodistribution and clearance of liposomal gadolinium-DTPA. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354925/),d,3 to 4,92655,DB00789,Gadopentetate dimeglumine
>,16027440,plasma AUC(0-24),"Using a conservative a priori assumption that a > or = 50% decrease in K(trans) was indicative of an objective vascular response, a 50% decrease in K(trans) was achieved and corresponded to a plasma AUC(0-24) of > 200 ng .","Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027440/),ng,200,94213,DB00789,Gadopentetate dimeglumine
,11378881,half-lives,"Kinetics in blood was biexponential with median half-lives of 21 sec and 11.1 min, respectively.",Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11378881/),s,21,103777,DB00789,Gadopentetate dimeglumine
,11378881,half-lives,"Kinetics in blood was biexponential with median half-lives of 21 sec and 11.1 min, respectively.",Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11378881/),min,11.1,103778,DB00789,Gadopentetate dimeglumine
,11378881,MRT*,"MRT* (reference estimate) was 1.0 (0-1.5), 1.9 (1.5-2.3), and 2.5 (2.3-2.8) min in carcinomas, fibroadenomas, and mastopathies, respectively (median and interquartile distance).",Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11378881/),min,1.0,103779,DB00789,Gadopentetate dimeglumine
,11378881,MRT*,"MRT* (reference estimate) was 1.0 (0-1.5), 1.9 (1.5-2.3), and 2.5 (2.3-2.8) min in carcinomas, fibroadenomas, and mastopathies, respectively (median and interquartile distance).",Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11378881/),min,1.9,103780,DB00789,Gadopentetate dimeglumine
,11378881,MRT*,"MRT* (reference estimate) was 1.0 (0-1.5), 1.9 (1.5-2.3), and 2.5 (2.3-2.8) min in carcinomas, fibroadenomas, and mastopathies, respectively (median and interquartile distance).",Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11378881/),min,2.5,103781,DB00789,Gadopentetate dimeglumine
,8428078,half-time,Pulmonary clearance of aerosolized gadopentetate dimeglumine was monoexponential with a half-time of 2.16 hours.,Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428078/),h,2.16,110589,DB00789,Gadopentetate dimeglumine
,7478129,total gadolinium clearance,The corresponding total gadolinium clearance was 12.8 ml/min and 15.8 ml/min respectively.,Elimination of gadolinium-DTPA by peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7478129/),[ml] / [min],12.8,111520,DB00789,Gadopentetate dimeglumine
,7478129,total gadolinium clearance,The corresponding total gadolinium clearance was 12.8 ml/min and 15.8 ml/min respectively.,Elimination of gadolinium-DTPA by peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7478129/),[ml] / [min],15.8,111521,DB00789,Gadopentetate dimeglumine
,7478129,clearance rate,Gadolinium-DTPA was removed from the body through peritoneal dialysis at a mean clearance rate of 5.13 ml/min.,Elimination of gadolinium-DTPA by peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7478129/),[ml] / [min],5.13,111522,DB00789,Gadopentetate dimeglumine
,7478129,Plasma half-life,Plasma half-life of gadolinium-DTPA was prolonged to 9 h.,Elimination of gadolinium-DTPA by peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7478129/),h,9,111523,DB00789,Gadopentetate dimeglumine
,2254055,total body clearance,The estimated total body clearance of gadopentetate dimeglumine was 14.1 +/- 0.56 cc/minute for the normal animals and 3.78 +/- 0.19 cc/minute for the impaired rabbits.,Gadopentetate dimeglumine clearance in renal insufficiency in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2254055/),[cc] / [min],14.1,120688,DB00789,Gadopentetate dimeglumine
,2254055,total body clearance,The estimated total body clearance of gadopentetate dimeglumine was 14.1 +/- 0.56 cc/minute for the normal animals and 3.78 +/- 0.19 cc/minute for the impaired rabbits.,Gadopentetate dimeglumine clearance in renal insufficiency in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2254055/),[cc] / [min],3.78,120689,DB00789,Gadopentetate dimeglumine
,8596833,blood half-life,Mean blood half-life was 2 hours.,Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8596833/),h,2,126235,DB00789,Gadopentetate dimeglumine
,8596833,Maximum accumulation,Maximum accumulation in peripheral (33.0% injected dose [ID]/g +/- 16.2 [standard deviation]) and central lymph nodes (63.2% ID/g +/- 16.5) was observed within 24 hours after administration.,Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8596833/),%,33.0,126236,DB00789,Gadopentetate dimeglumine
,8596833,Maximum accumulation,Maximum accumulation in peripheral (33.0% injected dose [ID]/g +/- 16.2 [standard deviation]) and central lymph nodes (63.2% ID/g +/- 16.5) was observed within 24 hours after administration.,Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8596833/),%,63.2,126237,DB00789,Gadopentetate dimeglumine
,8596833,signal-to-noise ratio,"At 24 hours after administration of 20 mumol Gd/kg, the signal-to-noise ratio increased from 30.9 +/- 0.4 to 83.2 +/- 5.2 in normal lymph nodes (P < .001).",Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8596833/),,30.9,126238,DB00789,Gadopentetate dimeglumine
,8596833,signal-to-noise ratio,"At 24 hours after administration of 20 mumol Gd/kg, the signal-to-noise ratio increased from 30.9 +/- 0.4 to 83.2 +/- 5.2 in normal lymph nodes (P < .001).",Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8596833/),,83.2,126239,DB00789,Gadopentetate dimeglumine
,8377117,renal clearance,"However, for both dose groups tested, the values of renal clearance (9.96 and 11.1 mL/min.kg, respectively) were close to the value of glomerular filtration in the rat.",Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377117/),[ml] / [kg·min],9.96,136845,DB00789,Gadopentetate dimeglumine
,8377117,renal clearance,"However, for both dose groups tested, the values of renal clearance (9.96 and 11.1 mL/min.kg, respectively) were close to the value of glomerular filtration in the rat.",Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377117/),[ml] / [kg·min],11.1,136846,DB00789,Gadopentetate dimeglumine
,8377117,hepatobiliary transport maximum,A hepatobiliary transport maximum of 9.2 mumol/min.kg was evaluated by infusion studies.,Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377117/),[μM] / [kg·min],9.2,136847,DB00789,Gadopentetate dimeglumine
,8821523,elimination half-live,"Following intravenous dosing of NaCa DTPA-BMA (0.015 mmol/kg) in a 14C-labeled form, plasma concentrations of the drug declined rapidly with an elimination half-live of 0.31 h, a distribution volume of 244 ml/kg and a plasma clearance of 9.2 ml/min/kg.",Pharmacokinetics and stability of caldiamide sodium in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8821523/),h,0.31,136928,DB00789,Gadopentetate dimeglumine
,8821523,distribution volume,"Following intravenous dosing of NaCa DTPA-BMA (0.015 mmol/kg) in a 14C-labeled form, plasma concentrations of the drug declined rapidly with an elimination half-live of 0.31 h, a distribution volume of 244 ml/kg and a plasma clearance of 9.2 ml/min/kg.",Pharmacokinetics and stability of caldiamide sodium in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8821523/),[ml] / [kg],244,136929,DB00789,Gadopentetate dimeglumine
,8821523,plasma clearance,"Following intravenous dosing of NaCa DTPA-BMA (0.015 mmol/kg) in a 14C-labeled form, plasma concentrations of the drug declined rapidly with an elimination half-live of 0.31 h, a distribution volume of 244 ml/kg and a plasma clearance of 9.2 ml/min/kg.",Pharmacokinetics and stability of caldiamide sodium in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8821523/),[ml] / [kg·min],9.2,136930,DB00789,Gadopentetate dimeglumine
,8748492,TR/TE,"In T1-weighed MR images (TR/TE = 400/18 msec), an average signal enhancement of 34% in the kidneys and 20% in the liver was observed, which persisted for at least 90 minutes after administration of the PPLs.",Paramagnetic polymerized liposomes as new recirculating MR contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748492/),ms,400,146585,DB00789,Gadopentetate dimeglumine
,8748492,TR/TE,"In T1-weighed MR images (TR/TE = 400/18 msec), an average signal enhancement of 34% in the kidneys and 20% in the liver was observed, which persisted for at least 90 minutes after administration of the PPLs.",Paramagnetic polymerized liposomes as new recirculating MR contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748492/),ms,18,146586,DB00789,Gadopentetate dimeglumine
,8748492,half-life of elimination,The half-life of elimination from the blood pool was 19 hours.,Paramagnetic polymerized liposomes as new recirculating MR contrast agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748492/),h,19,146587,DB00789,Gadopentetate dimeglumine
,23888476,relative peak enhancement,"The relative peak enhancement was in the PZ (Gd-DTPA 1.4 a. u. [1.20; 1.59], gadobutrol 1.58 a. u. [1.37; 1.78]) and in PCa foci (Gd-DTPA 1.56 a. u. [1.41; 1.71], gadobutrol 1.76 a. u. [1.59; 1.94]) significantly higher with gadobutrol (p = 0.04).",Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23888476/),a·u,1.4,149053,DB00789,Gadopentetate dimeglumine
,23888476,relative peak enhancement,"The relative peak enhancement was in the PZ (Gd-DTPA 1.4 a. u. [1.20; 1.59], gadobutrol 1.58 a. u. [1.37; 1.78]) and in PCa foci (Gd-DTPA 1.56 a. u. [1.41; 1.71], gadobutrol 1.76 a. u. [1.59; 1.94]) significantly higher with gadobutrol (p = 0.04).",Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23888476/),a·u,1.58,149054,DB00789,Gadopentetate dimeglumine
,23888476,relative peak enhancement,"The relative peak enhancement was in the PZ (Gd-DTPA 1.4 a. u. [1.20; 1.59], gadobutrol 1.58 a. u. [1.37; 1.78]) and in PCa foci (Gd-DTPA 1.56 a. u. [1.41; 1.71], gadobutrol 1.76 a. u. [1.59; 1.94]) significantly higher with gadobutrol (p = 0.04).",Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23888476/),a·u,1.56,149055,DB00789,Gadopentetate dimeglumine
,23888476,relative peak enhancement,"The relative peak enhancement was in the PZ (Gd-DTPA 1.4 a. u. [1.20; 1.59], gadobutrol 1.58 a. u. [1.37; 1.78]) and in PCa foci (Gd-DTPA 1.56 a. u. [1.41; 1.71], gadobutrol 1.76 a. u. [1.59; 1.94]) significantly higher with gadobutrol (p = 0.04).",Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23888476/),a·u,1.76,149056,DB00789,Gadopentetate dimeglumine
,24056116,Michaelis-Menten constant [K(m)],"In vitro, Gd-EOB-DTPA was demonstrated to be a substrate for OATP1A2 (mean [SD] of the Michaelis-Menten constant [K(m)], 1.0 [0.4] mmol/L; mean [SD] of the maximal uptake rate [V(max)], 101.3 [21.1] pmol/mg per minute), MRP2 (K(m), 1.0 [0.5] mmol/L; V(max), 86.8 [31.1] pmol/mg per minute), and multidrug resistance-associated protein 3 (K(m), 1.8 [0.3] mmol/L; V(max), 116 [15.9] pmol/mg per minute) but not for the apical sodium-dependent bile acid transporter and organic cation transporter 3.",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),[mM] / [l],1.0,149730,DB00789,Gadopentetate dimeglumine
,24056116,maximal uptake rate [V(max)],"In vitro, Gd-EOB-DTPA was demonstrated to be a substrate for OATP1A2 (mean [SD] of the Michaelis-Menten constant [K(m)], 1.0 [0.4] mmol/L; mean [SD] of the maximal uptake rate [V(max)], 101.3 [21.1] pmol/mg per minute), MRP2 (K(m), 1.0 [0.5] mmol/L; V(max), 86.8 [31.1] pmol/mg per minute), and multidrug resistance-associated protein 3 (K(m), 1.8 [0.3] mmol/L; V(max), 116 [15.9] pmol/mg per minute) but not for the apical sodium-dependent bile acid transporter and organic cation transporter 3.",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),[pM] / [mg·min],101.3,149731,DB00789,Gadopentetate dimeglumine
,24056116,K(m),"In vitro, Gd-EOB-DTPA was demonstrated to be a substrate for OATP1A2 (mean [SD] of the Michaelis-Menten constant [K(m)], 1.0 [0.4] mmol/L; mean [SD] of the maximal uptake rate [V(max)], 101.3 [21.1] pmol/mg per minute), MRP2 (K(m), 1.0 [0.5] mmol/L; V(max), 86.8 [31.1] pmol/mg per minute), and multidrug resistance-associated protein 3 (K(m), 1.8 [0.3] mmol/L; V(max), 116 [15.9] pmol/mg per minute) but not for the apical sodium-dependent bile acid transporter and organic cation transporter 3.",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),[mM] / [l],1.0,149732,DB00789,Gadopentetate dimeglumine
,24056116,V(max),"In vitro, Gd-EOB-DTPA was demonstrated to be a substrate for OATP1A2 (mean [SD] of the Michaelis-Menten constant [K(m)], 1.0 [0.4] mmol/L; mean [SD] of the maximal uptake rate [V(max)], 101.3 [21.1] pmol/mg per minute), MRP2 (K(m), 1.0 [0.5] mmol/L; V(max), 86.8 [31.1] pmol/mg per minute), and multidrug resistance-associated protein 3 (K(m), 1.8 [0.3] mmol/L; V(max), 116 [15.9] pmol/mg per minute) but not for the apical sodium-dependent bile acid transporter and organic cation transporter 3.",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),[pM] / [mg·min],86.8,149733,DB00789,Gadopentetate dimeglumine
,24056116,K(m),"In vitro, Gd-EOB-DTPA was demonstrated to be a substrate for OATP1A2 (mean [SD] of the Michaelis-Menten constant [K(m)], 1.0 [0.4] mmol/L; mean [SD] of the maximal uptake rate [V(max)], 101.3 [21.1] pmol/mg per minute), MRP2 (K(m), 1.0 [0.5] mmol/L; V(max), 86.8 [31.1] pmol/mg per minute), and multidrug resistance-associated protein 3 (K(m), 1.8 [0.3] mmol/L; V(max), 116 [15.9] pmol/mg per minute) but not for the apical sodium-dependent bile acid transporter and organic cation transporter 3.",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),[mM] / [l],1.8,149734,DB00789,Gadopentetate dimeglumine
,24056116,V(max),"In vitro, Gd-EOB-DTPA was demonstrated to be a substrate for OATP1A2 (mean [SD] of the Michaelis-Menten constant [K(m)], 1.0 [0.4] mmol/L; mean [SD] of the maximal uptake rate [V(max)], 101.3 [21.1] pmol/mg per minute), MRP2 (K(m), 1.0 [0.5] mmol/L; V(max), 86.8 [31.1] pmol/mg per minute), and multidrug resistance-associated protein 3 (K(m), 1.8 [0.3] mmol/L; V(max), 116 [15.9] pmol/mg per minute) but not for the apical sodium-dependent bile acid transporter and organic cation transporter 3.",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),[pM] / [mg·min],116,149735,DB00789,Gadopentetate dimeglumine
,24056116,bioavailability,"After the oral administration to the wild-type animals, Gd-EOB-DTPA was considerably absorbed from the small intestine (bioavailability, approximately 17%) and predominately eliminated via feces after intravenous dosing (approximately 96%).",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),%,17,149736,DB00789,Gadopentetate dimeglumine
,24056116,bioavailability,"After the oral administration to the wild-type animals, Gd-EOB-DTPA was considerably absorbed from the small intestine (bioavailability, approximately 17%) and predominately eliminated via feces after intravenous dosing (approximately 96%).",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),%,96,149737,DB00789,Gadopentetate dimeglumine
,24056116,oral bioavailability,"In the Mrp2-deficient rats, oral bioavailability increased to approximately 21% and Gd-EOB-DTPA was exclusively excreted into urine.",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),%,21,149738,DB00789,Gadopentetate dimeglumine
,24056116,area under the curve0-90,"Magnetic resonance enhancement of the liver was significantly prolonged in the Mrp2-deficient rats compared with the wild-type rats (mean [SD] area under the curve0-90, 36.4 [8.5] vs 14.8 [10.3] arbitary units per minute; P = 0.003; time to maximum plasma concentration, 48.6 [23.8] vs 6.0 [3.1] minutes; P = 0.001).",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),[arbitary·units] / [min],36.4,149739,DB00789,Gadopentetate dimeglumine
,24056116,area under the curve0-90,"Magnetic resonance enhancement of the liver was significantly prolonged in the Mrp2-deficient rats compared with the wild-type rats (mean [SD] area under the curve0-90, 36.4 [8.5] vs 14.8 [10.3] arbitary units per minute; P = 0.003; time to maximum plasma concentration, 48.6 [23.8] vs 6.0 [3.1] minutes; P = 0.001).",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),[arbitary·units] / [min],14.8,149740,DB00789,Gadopentetate dimeglumine
,24056116,time to maximum plasma concentration,"Magnetic resonance enhancement of the liver was significantly prolonged in the Mrp2-deficient rats compared with the wild-type rats (mean [SD] area under the curve0-90, 36.4 [8.5] vs 14.8 [10.3] arbitary units per minute; P = 0.003; time to maximum plasma concentration, 48.6 [23.8] vs 6.0 [3.1] minutes; P = 0.001).",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),min,48.6,149741,DB00789,Gadopentetate dimeglumine
,24056116,time to maximum plasma concentration,"Magnetic resonance enhancement of the liver was significantly prolonged in the Mrp2-deficient rats compared with the wild-type rats (mean [SD] area under the curve0-90, 36.4 [8.5] vs 14.8 [10.3] arbitary units per minute; P = 0.003; time to maximum plasma concentration, 48.6 [23.8] vs 6.0 [3.1] minutes; P = 0.001).",Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24056116/),min,6.0,149742,DB00789,Gadopentetate dimeglumine
,2394576,elimination half-time,Gd-DTPASA liposomes had an elimination half-time from the liver of 61 hours.,"A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394576/),h,61,157575,DB00789,Gadopentetate dimeglumine
,2394576,elimination half-time,"Manganese liposomes produced stronger contrast at lower concentrations and had faster elimination kinetics from the liver, with a major elimination half-time of 10 hours.","A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394576/),h,10,157576,DB00789,Gadopentetate dimeglumine
,21290457,area under the curve,The area under the curve of the first-pass bolus ranged between 0.6 min mM at HCT = 0.53 and 1.3 min mM at HCT = 0.39.,Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290457/),mM·min,0.6,160616,DB00789,Gadopentetate dimeglumine
,21290457,area under the curve,The area under the curve of the first-pass bolus ranged between 0.6 min mM at HCT = 0.53 and 1.3 min mM at HCT = 0.39.,Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290457/),mM·min,1.3,160617,DB00789,Gadopentetate dimeglumine
,21290457,HCT,"Significant differences in magnitude at peak contrast agent concentrations (HCT = 0.36, [Gd-DTPA-BMA](max) = 9 ± 0.4 mM; HCT = 0.46, [Gd-DTPA-BMA](max) = 4.0 ± 0.2 mM) were found.",Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290457/),,0.36,160618,DB00789,Gadopentetate dimeglumine
,21290457,],"Significant differences in magnitude at peak contrast agent concentrations (HCT = 0.36, [Gd-DTPA-BMA](max) = 9 ± 0.4 mM; HCT = 0.46, [Gd-DTPA-BMA](max) = 4.0 ± 0.2 mM) were found.",Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290457/),mM,9,160619,DB00789,Gadopentetate dimeglumine
,21290457,(max),"Significant differences in magnitude at peak contrast agent concentrations (HCT = 0.36, [Gd-DTPA-BMA](max) = 9 ± 0.4 mM; HCT = 0.46, [Gd-DTPA-BMA](max) = 4.0 ± 0.2 mM) were found.",Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290457/),mM,9,160620,DB00789,Gadopentetate dimeglumine
,21290457,HCT,"Significant differences in magnitude at peak contrast agent concentrations (HCT = 0.36, [Gd-DTPA-BMA](max) = 9 ± 0.4 mM; HCT = 0.46, [Gd-DTPA-BMA](max) = 4.0 ± 0.2 mM) were found.",Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290457/),,0.46,160621,DB00789,Gadopentetate dimeglumine
,21290457,(max),"Significant differences in magnitude at peak contrast agent concentrations (HCT = 0.36, [Gd-DTPA-BMA](max) = 9 ± 0.4 mM; HCT = 0.46, [Gd-DTPA-BMA](max) = 4.0 ± 0.2 mM) were found.",Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290457/),mM,4.0,160622,DB00789,Gadopentetate dimeglumine
,27109487,half-life,"We found that the PK of Gd-DTPA (i.v. 0.025mmol/kg) had a half-life of 37.3±6.6min, and was a better fit into a linear T1-[Gd-DTPA] relationship than higher doses (up to 0.1mmol/kg).",Analysis of pharmacokinetics of Gd-DTPA for dynamic contrast-enhanced magnetic resonance imaging. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27109487/),min,37.3,162992,DB00789,Gadopentetate dimeglumine
,27109487,area under the curve (AUC),"The area under the curve (AUC) for 0.025mmol/kg was 3.37±0.46, which was a quarter of AUC of 0.1mmol/kg.",Analysis of pharmacokinetics of Gd-DTPA for dynamic contrast-enhanced magnetic resonance imaging. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27109487/),,3.37,162993,DB00789,Gadopentetate dimeglumine
,9660563,relaxation rate constant,Longitudinal relaxation rate constant of human RBCs increased from 2.0 +/- 0.1 to 145.6 +/- 36.2 s(-1); the transverse relaxation rate constant increased from 6.8 +/- 1.2 to 562 +/- 410 s(-1).,Gadolinium-bearing red cells as blood pool MRI contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),1/[s],2.0,179082,DB00789,Gadopentetate dimeglumine
,9660563,relaxation rate constant,Longitudinal relaxation rate constant of human RBCs increased from 2.0 +/- 0.1 to 145.6 +/- 36.2 s(-1); the transverse relaxation rate constant increased from 6.8 +/- 1.2 to 562 +/- 410 s(-1).,Gadolinium-bearing red cells as blood pool MRI contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),1/[s],145.6,179083,DB00789,Gadopentetate dimeglumine
,9660563,transverse relaxation rate constant,Longitudinal relaxation rate constant of human RBCs increased from 2.0 +/- 0.1 to 145.6 +/- 36.2 s(-1); the transverse relaxation rate constant increased from 6.8 +/- 1.2 to 562 +/- 410 s(-1).,Gadolinium-bearing red cells as blood pool MRI contrast agents. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),1/[s],6.8,179084,DB00789,Gadopentetate dimeglumine
,9660563,transverse relaxation rate constant,Longitudinal relaxation rate constant of human RBCs increased from 2.0 +/- 0.1 to 145.6 +/- 36.2 s(-1); the transverse relaxation rate constant increased from 6.8 +/- 1.2 to 562 +/- 410 s(-1).,Gadolinium-bearing red cells as blood pool MRI contrast agents. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),1/[s],562,179085,DB00789,Gadopentetate dimeglumine
,9660563,R1,"For rat RBCs, R1 increased from 1.45 +/- 0.15 to 84.8 +/- 23.9 s(-1); R2 increased from 7.1 +/- 0.64 to 247 +/- 158 s(-1).",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),1/[s],1.45,179086,DB00789,Gadopentetate dimeglumine
,9660563,R1,"For rat RBCs, R1 increased from 1.45 +/- 0.15 to 84.8 +/- 23.9 s(-1); R2 increased from 7.1 +/- 0.64 to 247 +/- 158 s(-1).",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),1/[s],84.8,179087,DB00789,Gadopentetate dimeglumine
,9660563,R2,"For rat RBCs, R1 increased from 1.45 +/- 0.15 to 84.8 +/- 23.9 s(-1); R2 increased from 7.1 +/- 0.64 to 247 +/- 158 s(-1).",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),1/[s],7.1,179088,DB00789,Gadopentetate dimeglumine
,9660563,R2,"For rat RBCs, R1 increased from 1.45 +/- 0.15 to 84.8 +/- 23.9 s(-1); R2 increased from 7.1 +/- 0.64 to 247 +/- 158 s(-1).",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),1/[s],247,179089,DB00789,Gadopentetate dimeglumine
,9660563,P50,"Affinity for oxygen was slightly reduced (control P50 = 22.3 +/- 2.3 versus experimental P50 = 27.3 +/- 1.3, P < 0.01), as was mechanical deformability.",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),,22.3,179090,DB00789,Gadopentetate dimeglumine
,9660563,P50,"Affinity for oxygen was slightly reduced (control P50 = 22.3 +/- 2.3 versus experimental P50 = 27.3 +/- 1.3, P < 0.01), as was mechanical deformability.",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),,27.3,179091,DB00789,Gadopentetate dimeglumine
,9660563,apparent volume of distribution,"The apparent volume of distribution was 0.0164 +/- 0.003 liter/kg, biologic half-life 4.38 +/- 0.34 h, and total plasma clearance 0.003 +/- 0.0006 liter/kg/h.",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),[l] / [kg],0.0164,179092,DB00789,Gadopentetate dimeglumine
,9660563,biologic half-life,"The apparent volume of distribution was 0.0164 +/- 0.003 liter/kg, biologic half-life 4.38 +/- 0.34 h, and total plasma clearance 0.003 +/- 0.0006 liter/kg/h.",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),h,4.38,179093,DB00789,Gadopentetate dimeglumine
,9660563,total plasma clearance,"The apparent volume of distribution was 0.0164 +/- 0.003 liter/kg, biologic half-life 4.38 +/- 0.34 h, and total plasma clearance 0.003 +/- 0.0006 liter/kg/h.",Gadolinium-bearing red cells as blood pool MRI contrast agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660563/),[l] / [h·kg],0.003,179094,DB00789,Gadopentetate dimeglumine
,3340763,distribution half-life,"In rats, the biodistribution of Gd-DOTA was similar to Gd-DTPA with a distribution half-life of 3 minutes and an elimination half-life of 18 minutes.",Gd-DOTA: characterization of a new paramagnetic complex. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3340763/),min,3,179318,DB00789,Gadopentetate dimeglumine
,3340763,elimination half-life,"In rats, the biodistribution of Gd-DOTA was similar to Gd-DTPA with a distribution half-life of 3 minutes and an elimination half-life of 18 minutes.",Gd-DOTA: characterization of a new paramagnetic complex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3340763/),min,18,179319,DB00789,Gadopentetate dimeglumine
,3340763,ratio of LD50 to effective dose,The median lethal dose (LD50) in mice of Gd-DOTA was 93% higher than that of Gd-DTPA; the calculated safety factor (ratio of LD50 to effective dose) was 53 for Gd-DOTA and 28 for Gd-DTPA.,Gd-DOTA: characterization of a new paramagnetic complex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3340763/),,53,179320,DB00789,Gadopentetate dimeglumine
,3340763,ratio of LD50 to effective dose,The median lethal dose (LD50) in mice of Gd-DOTA was 93% higher than that of Gd-DTPA; the calculated safety factor (ratio of LD50 to effective dose) was 53 for Gd-DOTA and 28 for Gd-DTPA.,Gd-DOTA: characterization of a new paramagnetic complex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3340763/),,28,179321,DB00789,Gadopentetate dimeglumine
,12139457,r1,Both classes of agents were characterized by enhanced relaxivity in the presence of 4.5% HSA (r1 = 16-42 mM(-1) s(-1) at 20 MHz and 37 degrees C) as compared with the relaxivity values measured in phosphate-buffered saline (PBS) alone (r1 = 4.6-6.6 mM(-1) s(-1) at 20 MHz and 37 degrees C).,"The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),1/[mM·s],16-42,180796,DB00789,Gadopentetate dimeglumine
,12139457,r1,Both classes of agents were characterized by enhanced relaxivity in the presence of 4.5% HSA (r1 = 16-42 mM(-1) s(-1) at 20 MHz and 37 degrees C) as compared with the relaxivity values measured in phosphate-buffered saline (PBS) alone (r1 = 4.6-6.6 mM(-1) s(-1) at 20 MHz and 37 degrees C).,"The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),1/[mM·s],4.6-6.6,180797,DB00789,Gadopentetate dimeglumine
,12139457,half-life,Pharmacokinetic data indicated that compound 5b had a half-life of 14.3 +/- 1.8 min in the rat as compared with a half-life of 6.20 +/- 0.04 min for the non-phosphodiester analogue 11a.,"The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),min,14.3,180798,DB00789,Gadopentetate dimeglumine
,12139457,half-life,Pharmacokinetic data indicated that compound 5b had a half-life of 14.3 +/- 1.8 min in the rat as compared with a half-life of 6.20 +/- 0.04 min for the non-phosphodiester analogue 11a.,"The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),min,6.20,180799,DB00789,Gadopentetate dimeglumine
,12139457,half-life,"Similarly, the half-life obtained for the phosphodiester 5c was 14.3 +/- 1.7 min as compared with a half-life of 6.80 +/- 0.03 min for 11b.","The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),min,14.3,180800,DB00789,Gadopentetate dimeglumine
,12139457,half-life,"Similarly, the half-life obtained for the phosphodiester 5c was 14.3 +/- 1.7 min as compared with a half-life of 6.80 +/- 0.03 min for 11b.","The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),min,6.80,180801,DB00789,Gadopentetate dimeglumine
,12139457,percent biliary excretion,"The percent biliary excretion was significantly lower for the phosphodiester compounds than for non-phosphodiester analogues (17.7 +/- 4.0 and 66.9 +/- 3.4% for 5b and 11a, respectively; 17.0 +/- 1.6 and 64.3 +/- 9.0% for 5c and 11b, respectively).","The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),%,17.7,180802,DB00789,Gadopentetate dimeglumine
,12139457,percent biliary excretion,"The percent biliary excretion was significantly lower for the phosphodiester compounds than for non-phosphodiester analogues (17.7 +/- 4.0 and 66.9 +/- 3.4% for 5b and 11a, respectively; 17.0 +/- 1.6 and 64.3 +/- 9.0% for 5c and 11b, respectively).","The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),%,66.9,180803,DB00789,Gadopentetate dimeglumine
,12139457,percent biliary excretion,"The percent biliary excretion was significantly lower for the phosphodiester compounds than for non-phosphodiester analogues (17.7 +/- 4.0 and 66.9 +/- 3.4% for 5b and 11a, respectively; 17.0 +/- 1.6 and 64.3 +/- 9.0% for 5c and 11b, respectively).","The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),%,17.0,180804,DB00789,Gadopentetate dimeglumine
,12139457,percent biliary excretion,"The percent biliary excretion was significantly lower for the phosphodiester compounds than for non-phosphodiester analogues (17.7 +/- 4.0 and 66.9 +/- 3.4% for 5b and 11a, respectively; 17.0 +/- 1.6 and 64.3 +/- 9.0% for 5c and 11b, respectively).","The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),%,64.3,180805,DB00789,Gadopentetate dimeglumine
,12139457,percent biliary excretion,The percent biliary excretion (15.8 +/- 4.4%) and plasma half-life in the rat (23.1 +/- 2.9 min) for 5a are consistent with the extended plasma half-life of the other phosphodiester derivatives.,"The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),%,15.8,180806,DB00789,Gadopentetate dimeglumine
,12139457,plasma half-life,The percent biliary excretion (15.8 +/- 4.4%) and plasma half-life in the rat (23.1 +/- 2.9 min) for 5a are consistent with the extended plasma half-life of the other phosphodiester derivatives.,"The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139457/),min,23.1,180807,DB00789,Gadopentetate dimeglumine
<,22231729,k(ep),All benign SPNs had k(ep) < 1.0 min⁻¹.,Clinical application of pharmacokinetic analysis as a biomarker of solitary pulmonary nodules: dynamic contrast-enhanced MR imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22231729/),min⁻¹,1.0,187220,DB00789,Gadopentetate dimeglumine
>,22231729,k(ep),Nineteen of 25 (76%) malignant SPNs showed k(ep) > 1.0 min⁻¹.,Clinical application of pharmacokinetic analysis as a biomarker of solitary pulmonary nodules: dynamic contrast-enhanced MR imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22231729/),min⁻¹,1.0,187221,DB00789,Gadopentetate dimeglumine
,22231729,k(ep),"Sensitivity to diagnose malignant SPNs at a cutoff of k(ep) = 1.0 min⁻¹ was 76%, specificity was 100%, positive predictive value was 100%, negative predictive value was 45%, and accuracy was 80%.",Clinical application of pharmacokinetic analysis as a biomarker of solitary pulmonary nodules: dynamic contrast-enhanced MR imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22231729/),min⁻¹,1.0,187222,DB00789,Gadopentetate dimeglumine
,1617171,half-life,Average half-life was 1.87 hours.,[Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617171/),h,1.87,193755,DB00789,Gadopentetate dimeglumine
,12615626,Kep,"On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001).",Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615626/),1/[minutes],2.5 x 10(-3),200231,DB00789,Gadopentetate dimeglumine
,12615626,Kep,"On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001).",Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615626/),1/[minutes],1.7 x 10(-3),200232,DB00789,Gadopentetate dimeglumine
,12615626,T1/2,"On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001).",Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615626/),min,121.6,200233,DB00789,Gadopentetate dimeglumine
,12615626,T1/2,"On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001).",Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615626/),min,170.4,200234,DB00789,Gadopentetate dimeglumine
,26838894,plasma,"Gd-DTPA-Pullulan displayed the extended plasma half-life (t1/2,α=0.43 h, t1/2,β=2.32 h), much longer than 0.11h and 0.79 h of Gd-EOB-DTPA.",Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838894/),h,0.43,202730,DB00789,Gadopentetate dimeglumine
,26838894,"t1/2,β","Gd-DTPA-Pullulan displayed the extended plasma half-life (t1/2,α=0.43 h, t1/2,β=2.32 h), much longer than 0.11h and 0.79 h of Gd-EOB-DTPA.",Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838894/),h,2.32,202731,DB00789,Gadopentetate dimeglumine
,26838894,"t1/2,β","Gd-DTPA-Pullulan displayed the extended plasma half-life (t1/2,α=0.43 h, t1/2,β=2.32 h), much longer than 0.11h and 0.79 h of Gd-EOB-DTPA.",Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838894/),h,0.11,202732,DB00789,Gadopentetate dimeglumine
,26838894,"t1/2,β","Gd-DTPA-Pullulan displayed the extended plasma half-life (t1/2,α=0.43 h, t1/2,β=2.32 h), much longer than 0.11h and 0.79 h of Gd-EOB-DTPA.",Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838894/),h,0.79,202733,DB00789,Gadopentetate dimeglumine
,22864525,BMR,The IT-BMR (2.63 ± 1.22) was higher than the IV-BMR (1.46 ± 0.45) (p < 0.001).,Gadolinium distribution in cochlear perilymph: differences between intratympanic and intravenous gadolinium injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22864525/),,2.63,207312,DB00789,Gadopentetate dimeglumine
,22864525,BMR,The IT-BMR (2.63 ± 1.22) was higher than the IV-BMR (1.46 ± 0.45) (p < 0.001).,Gadolinium distribution in cochlear perilymph: differences between intratympanic and intravenous gadolinium injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22864525/),,1.46,207313,DB00789,Gadopentetate dimeglumine
,8684529,plasma clearance,"The plasma clearance of gadodiamide was 28.6 +/- (SD) 5.5 ml/min (n = 10), and the renal clearance (0-72 h) was 26.3 ml/min.",Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684529/),[ml] / [min],28.6,212915,DB00789,Gadopentetate dimeglumine
,8684529,renal clearance (0-72 h),"The plasma clearance of gadodiamide was 28.6 +/- (SD) 5.5 ml/min (n = 10), and the renal clearance (0-72 h) was 26.3 ml/min.",Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684529/),[ml] / [min],26.3,212916,DB00789,Gadopentetate dimeglumine
,8684529,renal clearance,The renal clearance of 125I-iothalamate for the same time period was 27.9 +/- 5.3 ml/min.,Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684529/),[ml] / [min],27.9,212917,DB00789,Gadopentetate dimeglumine
,1743920,LD50,The LD50 value of 17 mmol/kg reflects a fairly high acute intravenous tolerance of the macromolecular compound in mice.,In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743920/),[mM] / [kg],17,214270,DB00789,Gadopentetate dimeglumine
,12944603,half-lives,"The pharmacokinetic modeling indicated that the half-lives of Gd-DTPA entry and exit were identical (mean, 1.3 minutes +/- 0.9 [standard error of mean]) and shorter than those observed with Gd-BOPTA (P <.001).",Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12944603/),min,1.3,215495,DB00789,Gadopentetate dimeglumine
,12944603,half-life,"The uptake of Gd-BOPTA was faster (mean half-life, 4.8 minutes +/- 0.3) than the washout (mean half-life, 17.5 minutes +/- 2.8) (P =.001).",Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12944603/),min,4.8,215496,DB00789,Gadopentetate dimeglumine
,12944603,half-life,"The uptake of Gd-BOPTA was faster (mean half-life, 4.8 minutes +/- 0.3) than the washout (mean half-life, 17.5 minutes +/- 2.8) (P =.001).",Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12944603/),min,17.5,215497,DB00789,Gadopentetate dimeglumine
,2394577,plasma elimination half-life,"Its behavior was found to be similar to that of urographic and angiographic iodinated contrast media with a plasma elimination half-life of 91 +/- 14 minutes (mean +/- standard deviation [SD]), a small distribution volume of 171.0 +/- 19.7 mL/kg and rapid urinary excretion.",Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394577/),min,91,217458,DB00789,Gadopentetate dimeglumine
,2394577,distribution volume,"Its behavior was found to be similar to that of urographic and angiographic iodinated contrast media with a plasma elimination half-life of 91 +/- 14 minutes (mean +/- standard deviation [SD]), a small distribution volume of 171.0 +/- 19.7 mL/kg and rapid urinary excretion.",Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394577/),[ml] / [kg],171.0,217459,DB00789,Gadopentetate dimeglumine
,8216456,fecal elimination,"Extrarenal elimination played an important role since fecal elimination (% of dose) was 73.4 +/- 5.6 in rats (0.05 mmol/kg), 70.1 +/- 4.0 in dogs (0.03 mmol/kg) and 32.1 +/- 6.4 in monkeys (0.25 mmol/kg).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),%·dose,73.4,220225,DB00789,Gadopentetate dimeglumine
,8216456,fecal elimination,"Extrarenal elimination played an important role since fecal elimination (% of dose) was 73.4 +/- 5.6 in rats (0.05 mmol/kg), 70.1 +/- 4.0 in dogs (0.03 mmol/kg) and 32.1 +/- 6.4 in monkeys (0.25 mmol/kg).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),%·dose,70.1,220226,DB00789,Gadopentetate dimeglumine
,8216456,fecal elimination,"Extrarenal elimination played an important role since fecal elimination (% of dose) was 73.4 +/- 5.6 in rats (0.05 mmol/kg), 70.1 +/- 4.0 in dogs (0.03 mmol/kg) and 32.1 +/- 6.4 in monkeys (0.25 mmol/kg).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),%·dose,32.1,220227,DB00789,Gadopentetate dimeglumine
,8216456,g,"However, in all species investigated, the values of renal clearance (Clr) were independent of dose and close to the value of the glomerular filtration rate (Clr in ml/min.kg: 10.4 +/- 3.5 in rats; 3.88 +/- 0.8 in dogs; 1.01 +/- 0.3 in monkeys).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),[ml] / [kg·min],10.4,220228,DB00789,Gadopentetate dimeglumine
,8216456,g,"However, in all species investigated, the values of renal clearance (Clr) were independent of dose and close to the value of the glomerular filtration rate (Clr in ml/min.kg: 10.4 +/- 3.5 in rats; 3.88 +/- 0.8 in dogs; 1.01 +/- 0.3 in monkeys).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),[ml] / [kg·min],3.88,220229,DB00789,Gadopentetate dimeglumine
,8216456,g,"However, in all species investigated, the values of renal clearance (Clr) were independent of dose and close to the value of the glomerular filtration rate (Clr in ml/min.kg: 10.4 +/- 3.5 in rats; 3.88 +/- 0.8 in dogs; 1.01 +/- 0.3 in monkeys).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),[ml] / [kg·min],1.01,220230,DB00789,Gadopentetate dimeglumine
,8216456,plasma binding,"However, contrary to the latter agents the plasma binding (%) of Gd-EOB-DTPA was low in all species (10.3 +/- 1.4 in rats: 10.0 +/- 1.3 in dogs; 17.5 +/- 1.0 in monkeys).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),%,10.3,220231,DB00789,Gadopentetate dimeglumine
,8216456,plasma binding,"However, contrary to the latter agents the plasma binding (%) of Gd-EOB-DTPA was low in all species (10.3 +/- 1.4 in rats: 10.0 +/- 1.3 in dogs; 17.5 +/- 1.0 in monkeys).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),%,10.0,220232,DB00789,Gadopentetate dimeglumine
,8216456,plasma binding,"However, contrary to the latter agents the plasma binding (%) of Gd-EOB-DTPA was low in all species (10.3 +/- 1.4 in rats: 10.0 +/- 1.3 in dogs; 17.5 +/- 1.0 in monkeys).","Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216456/),%,17.5,220233,DB00789,Gadopentetate dimeglumine
,8011997,time,A rapid spin-echo sequence with a time resolution of 8.75 s was used for the dynamic examination.,[A pharmacokinetic analysis of Gd-DTPA enhancement in MRT in breast carcinoma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011997/),s,8.75,223772,DB00789,Gadopentetate dimeglumine
,21623212,Total clearance,"Total clearance of Gd-EOB-DTPA was significantly reduced to 140 ± 45 mL/min and terminal elimination half-life (t1/2) was slightly, but not significantly, increased to 2.6 ± 0.9 hours in patients with severe hepatic impairment (Child-Pugh C), compared with the control group (209 ± 37 mL/min and 1.8 ± 0.2 hours, respectively).",Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623212/),[ml] / [min],140,236750,DB00789,Gadopentetate dimeglumine
,21623212,terminal elimination half-life (t1/2),"Total clearance of Gd-EOB-DTPA was significantly reduced to 140 ± 45 mL/min and terminal elimination half-life (t1/2) was slightly, but not significantly, increased to 2.6 ± 0.9 hours in patients with severe hepatic impairment (Child-Pugh C), compared with the control group (209 ± 37 mL/min and 1.8 ± 0.2 hours, respectively).",Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623212/),h,2.6,236751,DB00789,Gadopentetate dimeglumine
,21623212,terminal elimination half-life (t1/2),"Total clearance of Gd-EOB-DTPA was significantly reduced to 140 ± 45 mL/min and terminal elimination half-life (t1/2) was slightly, but not significantly, increased to 2.6 ± 0.9 hours in patients with severe hepatic impairment (Child-Pugh C), compared with the control group (209 ± 37 mL/min and 1.8 ± 0.2 hours, respectively).",Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623212/),[ml] / [min],209,236752,DB00789,Gadopentetate dimeglumine
,21623212,terminal elimination half-life (t1/2),"Total clearance of Gd-EOB-DTPA was significantly reduced to 140 ± 45 mL/min and terminal elimination half-life (t1/2) was slightly, but not significantly, increased to 2.6 ± 0.9 hours in patients with severe hepatic impairment (Child-Pugh C), compared with the control group (209 ± 37 mL/min and 1.8 ± 0.2 hours, respectively).",Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623212/),h,1.8,236753,DB00789,Gadopentetate dimeglumine
,21623212,Peak liver enhancement,"Peak liver enhancement, however, was still at a high level (118% ± 57%).",Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623212/),%,118,236754,DB00789,Gadopentetate dimeglumine
,21623212,t1/2,"In patients with end-stage renal failure (ESRF), however, the PK profile of Gd-EOB-DTPA was significantly different, with an increased t1/2 (20.0 ± 7.0 hours vs. 1.8 ± 0.2 hours in the control group).",Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623212/),h,20.0,236755,DB00789,Gadopentetate dimeglumine
,21623212,t1/2,"In patients with end-stage renal failure (ESRF), however, the PK profile of Gd-EOB-DTPA was significantly different, with an increased t1/2 (20.0 ± 7.0 hours vs. 1.8 ± 0.2 hours in the control group).",Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623212/),h,1.8,236756,DB00789,Gadopentetate dimeglumine
,16958426,half-time,The average half-time of gadodiamide was 1.93 h (SD 0.55).,Dialyzability of gadodiamide in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958426/),h,1.93,237932,DB00789,Gadopentetate dimeglumine
,16958426,clearance,The mean clearance of gadodiamide during hemodialysis was 63.5 ml/min (SD 21.9).,Dialyzability of gadodiamide in hemodialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958426/),[ml] / [min],63.5,237933,DB00789,Gadopentetate dimeglumine
,10232516,MR,"MR perfusion rate kp significantly dropped under partial portal vein occlusion from an average of 11.3 to 4.9 min(-1) (P < 0.001), while the difference in amplitude A was not significant.",Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of dynamic MR images. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10232516/),1/[min],11.3,239381,DB00789,Gadopentetate dimeglumine
,10232516,perfusion rate kp,"MR perfusion rate kp significantly dropped under partial portal vein occlusion from an average of 11.3 to 4.9 min(-1) (P < 0.001), while the difference in amplitude A was not significant.",Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of dynamic MR images. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10232516/),1/[min],11.3,239382,DB00789,Gadopentetate dimeglumine
,10232516,perfusion rate kp,"MR perfusion rate kp significantly dropped under partial portal vein occlusion from an average of 11.3 to 4.9 min(-1) (P < 0.001), while the difference in amplitude A was not significant.",Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of dynamic MR images. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10232516/),1/[min],4.9,239383,DB00789,Gadopentetate dimeglumine
,1743921,recovery,"The recovery of Gd-DTPA in urine was 92.1% +/- 12.1% of the dose administered, and extrarenal elimination was less than 0.4%, indicating that glomerular filtration remains the predominant route of elimination.",Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743921/),%,92.1,246554,DB00789,Gadopentetate dimeglumine
less,1743921,extrarenal elimination,"The recovery of Gd-DTPA in urine was 92.1% +/- 12.1% of the dose administered, and extrarenal elimination was less than 0.4%, indicating that glomerular filtration remains the predominant route of elimination.",Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743921/),%,0.4,246555,DB00789,Gadopentetate dimeglumine
,31917760,HCL-GdA,"HCL-GdA of noncirrhosis and Child-Pugh class A (151.74 ± 68.28 mL/min, n = 26) was higher than that of Child-Pugh class B (54.54 ± 39.13 mL/min, n = 15; P = 0.001).",Dual Plasma Sampling Method to Determine the Hepatic and Renal Clearance of the 2 Diastereoisomers of Gd-EOB-DTPA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31917760/),[ml] / [min],151.74,249731,DB00789,Gadopentetate dimeglumine
,31917760,HCL-GdA,"HCL-GdA of noncirrhosis and Child-Pugh class A (151.74 ± 68.28 mL/min, n = 26) was higher than that of Child-Pugh class B (54.54 ± 39.13 mL/min, n = 15; P = 0.001).",Dual Plasma Sampling Method to Determine the Hepatic and Renal Clearance of the 2 Diastereoisomers of Gd-EOB-DTPA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31917760/),[ml] / [min],54.54,249732,DB00789,Gadopentetate dimeglumine
,9653466,elimination half-life,"In patients with severely reduced renal function, the elimination half-life of gadodiamide injection was prolonged (34.3 hours +/- 22.9) compared with data in healthy volunteers (1.3 hours +/- 0.25).",Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653466/),h,34.3,250590,DB00789,Gadopentetate dimeglumine
,9653466,elimination half-life,"In patients with severely reduced renal function, the elimination half-life of gadodiamide injection was prolonged (34.3 hours +/- 22.9) compared with data in healthy volunteers (1.3 hours +/- 0.25).",Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653466/),h,1.3,250591,DB00789,Gadopentetate dimeglumine
,8553955,t21,"Analysis of the pharmacokinetic mapping data showed significantly shorter (p < .005) and stronger (p < .001) contrast medium enhancement of malignant lesions (t21, 24 sec; A, 1.5 arbitrary units) than of benign lesions (t21, 65 sec; A, 0.7), resulting in a sensitivity of 100%, a specificity of 88%, and an accuracy of 96%.",Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8553955/),s,65,251362,DB00789,Gadopentetate dimeglumine
,15846467,alpha phase half-life,"The alpha phase half-life of Gd-(DTPA-BMA) and GDCC with molecular weights of 18,000 (GDCC-18) and 60,000 Da (GDCC-60) was 0.48 +/- 0.16 min, 1.08 +/- 0.24 min, and 1.74 +/- 0.57 min, and the beta phase half-life was 21.2 +/- 5.5 min, 26.5 +/- 5.9 min, and 53.7 +/- 15.9 min, respectively.","Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846467/),min,0.48,254512,DB00789,Gadopentetate dimeglumine
,15846467,alpha phase half-life,"The alpha phase half-life of Gd-(DTPA-BMA) and GDCC with molecular weights of 18,000 (GDCC-18) and 60,000 Da (GDCC-60) was 0.48 +/- 0.16 min, 1.08 +/- 0.24 min, and 1.74 +/- 0.57 min, and the beta phase half-life was 21.2 +/- 5.5 min, 26.5 +/- 5.9 min, and 53.7 +/- 15.9 min, respectively.","Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846467/),min,1.08,254513,DB00789,Gadopentetate dimeglumine
,15846467,alpha phase half-life,"The alpha phase half-life of Gd-(DTPA-BMA) and GDCC with molecular weights of 18,000 (GDCC-18) and 60,000 Da (GDCC-60) was 0.48 +/- 0.16 min, 1.08 +/- 0.24 min, and 1.74 +/- 0.57 min, and the beta phase half-life was 21.2 +/- 5.5 min, 26.5 +/- 5.9 min, and 53.7 +/- 15.9 min, respectively.","Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846467/),min,1.74,254514,DB00789,Gadopentetate dimeglumine
,15846467,beta phase half-life,"The alpha phase half-life of Gd-(DTPA-BMA) and GDCC with molecular weights of 18,000 (GDCC-18) and 60,000 Da (GDCC-60) was 0.48 +/- 0.16 min, 1.08 +/- 0.24 min, and 1.74 +/- 0.57 min, and the beta phase half-life was 21.2 +/- 5.5 min, 26.5 +/- 5.9 min, and 53.7 +/- 15.9 min, respectively.","Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846467/),min,21.2,254515,DB00789,Gadopentetate dimeglumine
,15846467,beta phase half-life,"The alpha phase half-life of Gd-(DTPA-BMA) and GDCC with molecular weights of 18,000 (GDCC-18) and 60,000 Da (GDCC-60) was 0.48 +/- 0.16 min, 1.08 +/- 0.24 min, and 1.74 +/- 0.57 min, and the beta phase half-life was 21.2 +/- 5.5 min, 26.5 +/- 5.9 min, and 53.7 +/- 15.9 min, respectively.","Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846467/),min,26.5,254516,DB00789,Gadopentetate dimeglumine
,15846467,beta phase half-life,"The alpha phase half-life of Gd-(DTPA-BMA) and GDCC with molecular weights of 18,000 (GDCC-18) and 60,000 Da (GDCC-60) was 0.48 +/- 0.16 min, 1.08 +/- 0.24 min, and 1.74 +/- 0.57 min, and the beta phase half-life was 21.2 +/- 5.5 min, 26.5 +/- 5.9 min, and 53.7 +/- 15.9 min, respectively.","Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846467/),min,53.7,254517,DB00789,Gadopentetate dimeglumine
,20173144,temporal resolution,"Fifty-three patients with biopsy-proven prostate cancer were examined with 1.5-T MRI performed with endorectal and body phased-array coils and a dynamic contrast-enhanced inversion-prepared dual-contrast gradient-echo sequence (temporal resolution, 1.65 seconds).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),seconds,1.65,256040,DB00789,Gadopentetate dimeglumine
,20173144,perfusion,"In patients with prostate cancer, median perfusion in the entire region was 0.71 mL/cm(3)min(-1) (hotspot, 1.53 mL/cm(3)min(-1)) with a median blood volume of 1.06% (hotspot, 2.23%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),[ml] / [cm(3)min],0.71,256041,DB00789,Gadopentetate dimeglumine
,20173144,perfusion,"In patients with prostate cancer, median perfusion in the entire region was 0.71 mL/cm(3)min(-1) (hotspot, 1.53 mL/cm(3)min(-1)) with a median blood volume of 1.06% (hotspot, 2.23%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),[ml] / [cm(3)min],1.53,256042,DB00789,Gadopentetate dimeglumine
,20173144,blood volume,"In patients with prostate cancer, median perfusion in the entire region was 0.71 mL/cm(3)min(-1) (hotspot, 1.53 mL/cm(3)min(-1)) with a median blood volume of 1.06% (hotspot, 2.23%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),%,1.06,256043,DB00789,Gadopentetate dimeglumine
,20173144,vessel density,"In the corresponding histologic areas, median mean vessel density was 77 vessels/mm(2) (hotspot, 156 vessels/mm(2)) with a median mean vessel area of 1.61% (hotspot, 2.50%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),[vessels] / [mm(2],77,256044,DB00789,Gadopentetate dimeglumine
,20173144,vessel density,"In the corresponding histologic areas, median mean vessel density was 77 vessels/mm(2) (hotspot, 156 vessels/mm(2)) with a median mean vessel area of 1.61% (hotspot, 2.50%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),[vessels] / [mm(2],156,256045,DB00789,Gadopentetate dimeglumine
,20173144,vessel area,"In the corresponding histologic areas, median mean vessel density was 77 vessels/mm(2) (hotspot, 156 vessels/mm(2)) with a median mean vessel area of 1.61% (hotspot, 2.50%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),%,1.61,256046,DB00789,Gadopentetate dimeglumine
,20173144,perfusion,"In normal prostate tissue, median perfusion was 0.33 mL/cm(3)min(-1) (hotspot, 1.38 mL/cm(3)min(-1)) with a median blood volume of 0.62% (hotspot, 2.6%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),[ml] / [cm(3)min],0.33,256047,DB00789,Gadopentetate dimeglumine
,20173144,perfusion,"In normal prostate tissue, median perfusion was 0.33 mL/cm(3)min(-1) (hotspot, 1.38 mL/cm(3)min(-1)) with a median blood volume of 0.62% (hotspot, 2.6%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),[ml] / [cm(3)min],1.38,256048,DB00789,Gadopentetate dimeglumine
,20173144,blood volume,"In normal prostate tissue, median perfusion was 0.33 mL/cm(3)min(-1) (hotspot, 1.38 mL/cm(3)min(-1)) with a median blood volume of 0.62% (hotspot, 2.6%).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),%,0.62,256049,DB00789,Gadopentetate dimeglumine
,20173144,vessel density,"In the corresponding histologic regions, median mean vessel density in the entire area was 57 vessels/mm(2) with a median mean vessel area of 1.21% (no hotspots).",Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173144/),[vessels] / [mm(2],57,256050,DB00789,Gadopentetate dimeglumine
,29442438,relaxivity,"High affinity for plasma protein and, in particular, the availability of more than one binding site, allows the complex to reach a fairly high relaxivity value in plasma (∼20 mm-1 s-1 , 20 MHz, 310 K) as well as to show unexpectedly enhanced properties of blood pooling, with an elimination half-life in rats approximately seven times longer than that of B22956/1.","Synthesis, Characterization, and Biodistribution of a Dinuclear Gadolinium Complex with Improved Properties as a Blood Pool MRI Agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442438/),1/[mm·s],∼20,258494,DB00789,Gadopentetate dimeglumine
,18022850,K(trans),"K(trans) values were (mean +/- SD) 1.06 +/- 0.62, 11.97 +/- 8.91, and 21.21 +/- 16.03 mL x minute(-1) x 100 mL(-1) (P < 0.02), respectively; and upsilon(e) values were 0.71 +/- 0.69, 3.59 +/- 2.21, and 10.51 +/- 8.20% (P < 0.002).",MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18022850/),[100·ml] / [minute·ml],1.06,261692,DB00789,Gadopentetate dimeglumine
,18022850,K(trans),"K(trans) values were (mean +/- SD) 1.06 +/- 0.62, 11.97 +/- 8.91, and 21.21 +/- 16.03 mL x minute(-1) x 100 mL(-1) (P < 0.02), respectively; and upsilon(e) values were 0.71 +/- 0.69, 3.59 +/- 2.21, and 10.51 +/- 8.20% (P < 0.002).",MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18022850/),[100·ml] / [minute·ml],11.97,261693,DB00789,Gadopentetate dimeglumine
,18022850,K(trans),"K(trans) values were (mean +/- SD) 1.06 +/- 0.62, 11.97 +/- 8.91, and 21.21 +/- 16.03 mL x minute(-1) x 100 mL(-1) (P < 0.02), respectively; and upsilon(e) values were 0.71 +/- 0.69, 3.59 +/- 2.21, and 10.51 +/- 8.20% (P < 0.002).",MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18022850/),[100·ml] / [minute·ml],21.21,261694,DB00789,Gadopentetate dimeglumine
,18022850,upsilon(e),"K(trans) values were (mean +/- SD) 1.06 +/- 0.62, 11.97 +/- 8.91, and 21.21 +/- 16.03 mL x minute(-1) x 100 mL(-1) (P < 0.02), respectively; and upsilon(e) values were 0.71 +/- 0.69, 3.59 +/- 2.21, and 10.51 +/- 8.20% (P < 0.002).",MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18022850/),%,0.71,261695,DB00789,Gadopentetate dimeglumine
,18022850,upsilon(e),"K(trans) values were (mean +/- SD) 1.06 +/- 0.62, 11.97 +/- 8.91, and 21.21 +/- 16.03 mL x minute(-1) x 100 mL(-1) (P < 0.02), respectively; and upsilon(e) values were 0.71 +/- 0.69, 3.59 +/- 2.21, and 10.51 +/- 8.20% (P < 0.002).",MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18022850/),%,3.59,261696,DB00789,Gadopentetate dimeglumine
,18022850,upsilon(e),"K(trans) values were (mean +/- SD) 1.06 +/- 0.62, 11.97 +/- 8.91, and 21.21 +/- 16.03 mL x minute(-1) x 100 mL(-1) (P < 0.02), respectively; and upsilon(e) values were 0.71 +/- 0.69, 3.59 +/- 2.21, and 10.51 +/- 8.20% (P < 0.002).",MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18022850/),%,10.51,261697,DB00789,Gadopentetate dimeglumine
